Screener
GeneDx Holdings WGS SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of services | 34,043 | 28,639 |
| Gross profit | 68,211 | 58,476 |
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
| Impairment loss | 31,287 | — |
| Loss from operations | (57,471) | (4,551) |
| Non-operating (expenses) income, net | ||
| Change in fair value of financial liabilities | 2,540 | (1,100) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's SG&A?
- GeneDx Holdings (WGS) reported SG&A of $74.59M in Q1 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about GeneDx Holdings's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude